five

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

收藏
DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/PR00009944/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.
提供机构:
Vivli
创建时间:
2024-04-03
二维码
社区交流群
二维码
科研交流群
商业服务